Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026Business Wire · Oct 19, 2026
Do Options Traders Know Something About Innoviva Stock We Don't?Zacks Investment Research · Oct 12, 2026
INVA vs. MRK: Which Stock Is the Better Value Option?Zacks Investment Research · Oct 8, 2026
5 Attractive Low Price-to-Sales Stocks With Promising Upside PotentialZacks Investment Research · Oct 8, 2026
Should Value Investors Buy Innoviva (INVA) Stock?Zacks Investment Research · Oct 8, 2026
Russian plague outbreak could boost these under-the-radar pharma stocksInvezz · Oct 5, 2026Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.44 | $1.14 | Beat |
| May 6, 2026 | $0.43 | $0.44 | Beat |
| Feb 25, 2026 | $0.34 | $1.94 | Beat |
| Nov 5, 2025 | $0.46 | $1.08 | Beat |
| Aug 6, 2025 | $0.57 | $0.77 | Beat |
| May 7, 2025 | $0.29 | $0.74 | Beat |